Samalizumab

DB12636InvestigationalProtein Based Therapies

Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.

Mechanism: Pharmacologically active on OX-2 membrane glycoprotein
Curator reviewed
Code names: ALXN6000

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Samalizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.